• PRINT: RNA-Mediated Safe-Harbor Transgene Insertion

  2026-10-10

  The reference study introduces PRINT, an RNA-mediated strategy that uses avian R2 retroelement proteins to direct transgene synthesis into a multicopy human safe-harbor locus. Its findings support a potentially lower-mutagenesis alternative to DNA donor delivery, while remaining limited to biochemical assays and cultured human cells rather than clinical validation.

• Cy3 Maleimide in H1 Replication-Stress Research

  2026-10-09

  Cy3 maleimide is a thiol-reactive fluorescent probe with potential conceptual value for visualizing labeled proteins, peptides, oligonucleotides, or biomolecular assemblies. The supplied H1 study, however, used site-specific photocrosslinking rather than Cy3 maleimide. This overview separates the published evidence on phosphorylated linker histone H1 from supplier-reported dye properties, then examines how fluorescence could complement—not replace—interaction mapping, biochemical assays, and cellular rescue experiments.

• Anti Reverse Cap Analog: Evidence and Limits

  2026-10-09

  Anti Reverse Cap Analog (ARCA), also called 3´-O-Me-m7G(5')ppp(5')G, is an orientation-selective cap analog used in synthetic mRNA research. Foundational studies support its ability to reduce reverse incorporation of cap analogs and improve translation in defined experimental systems. However, reported benefits are context-dependent and should not be treated as a universal twofold increase in protein output. The strongest evidence concerns cap orientation and translation initiation; evidence for mRNA stability enhancement, therapeutic performance, or superiority in mRNA therapeutics research is more conditional because sequence design, nucleotide chemistry, purification, delivery, and innate immune sensing also contribute. The supplied TCAIM study is not evidence about ARCA and should not be used to support claims about synthetic mRNA.

• CFDA SE Cell Tracer Kit: Product Overview

  2026-10-08

  The CFDA SE Cell Tracer Kit is a commercial fluorescent labeling product containing carboxyfluorescein diacetate succinimidyl ester (CFDA SE). Its documented scope includes conceptual cell tracking, cell proliferation studies, and lineage-tracing research, but no matched peer-reviewed paper evidence was supplied.

• Nicotinamide Riboside Chloride in RGC Research

  2026-10-08

  A source-grounded overview of Nicotinamide Riboside Chloride (NIAGEN), NAD+ metabolism, and retinal ganglion cell research, distinguishing published RGC differentiation findings from unconfirmed translational hypotheses.

• SARS-CoV-2 Variant Shifts in ACE2 Usage

  2026-10-07

  Shukla et al. developed a multiplexed pseudotyped-virus assay that measures how SARS-CoV-2 spike variants interact with diverse ACE2 orthologs and human sequence variants in parallel. Their results show modest changes in human ACE2 compatibility but substantially different compatibility patterns across animal ACE2 proteins, providing evidence that viral evolution can reshape potential host range.

• Nystatin (Fungicidin): Five Evidence Questions

  2026-10-07

  A source-grounded overview of Nystatin’s ergosterol-targeting principle, the evidence for moxidectin synergy, and the limits of translating laboratory and mouse findings into broader antifungal claims.

• P2RX1 and Mitochondrial Apoptosis in Ph+ ALL

  2026-10-06

  A 2025 Frontiers in Pediatrics study links P2RX1 activity with calcium dysregulation, CaMKII activation, PI3K/Akt suppression, and mitochondrial apoptosis in Philadelphia chromosome-positive acute lymphoblastic leukemia. Its findings provide a mechanistic framework for understanding tyrosine kinase inhibitor-associated cell death, while the single-cell-line and overexpression design limits immediate clinical generalization.

• P2RX1, CaMKII, and Mitochondrial Apoptosis in Ph+ ALL

  2026-10-06

  Li et al. report that P2RX1 overexpression increases tyrosine kinase inhibitor-associated mitochondrial apoptosis in Ph+ acute lymphoblastic leukemia cells through calcium dysregulation, CaMKII activation, and PI3K/Akt suppression. The study offers a mechanistic framework for understanding treatment sensitivity, while its single-cell-line design and database associations limit direct clinical translation.

• Liposomal Ce6-PDT, Pyroptosis, and Tumor Immunity

  2026-10-05

  A 2024 study reports that liposomal chlorin e6 photodynamic therapy links mitochondrial oxidative damage to caspase-1-associated pyroptosis in breast cancer models. The findings also connect this inflammatory cell-death pathway with immunogenic cell death and improved antitumor effects when combined with immune checkpoint inhibition, while remaining limited to preclinical evidence.

• Docetaxel (Taxotere): Mechanism and Evidence

  2026-10-05

  Docetaxel, also known as Taxotere, is a taxane that stabilizes microtubules and disrupts mitotic progression. Its research value is strongest when cytostatic effects, apoptosis, model context, and tumor-biology variables are interpreted as separate evidence streams.

• HMGCS2, LysoPC, and Pulmonary Fibrosis

  2026-10-04

  Yang et al. report that injured type II alveolar epithelial cells are a major source of accumulated lysophosphatidylcholines in experimental pulmonary fibrosis, linking epithelial lipid dysregulation to fibroblast activation. Their data support an HMGCS2–PPARα–CPT1A/CPT2 axis that influences lipid handling and disease progression, while leaving the contribution of individual LysoPC species and relevance to human disease open for further study.

• SR-202 and PPARγ: Evidence in IBD Research

  2026-10-03

  A source-grounded overview of SR-202 as a selective PPARγ antagonist, examining its reported role in octanoic acid-rich nutrition research, implications for macrophage biology and metabolic disease studies, and the limits of translating preclinical pathway evidence into clinical conclusions.

• Anti-Diabetic Drugs and Weight Loss in T2D

  2026-10-02

  This review organizes non-insulin glucose-lowering drugs by their observed weight-loss effects in patients with type 2 diabetes, linking pharmacological class with clinically relevant changes in body weight, BMI, and body composition. Its central finding is that weight reduction varies substantially across agents: ertugliflozin belongs to a moderate weight-loss group, whereas several GLP-1 receptor agonists produce larger average reductions.

• CLK2 and Platinum Resistance in Ovarian Cancer

  2026-10-01

  The reference study identifies Cdc2-like kinase 2 (CLK2) as a determinant of platinum resistance in ovarian cancer and links this phenotype to phosphorylation of BRCA1 at Ser1423. Its integrated tissue, cellular, mechanistic, and xenograft evidence suggests that CLK2 supports DNA damage repair and may provide a target for resistance-oriented research.

7892 records 1/527 page Next 12345 下5页 Last page